Zhao Liu
Neurology with Special Qualifications in Child Neurology · Columbia, MONPI 1114963394
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 32.9% of the total.
Across 79 payments — averaging $44.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$1K
- UCB, Inc.$493
- SK Life Science, Inc.$357
- Immedica Pharma US, Inc.$254
- Sentynl Therapeutics, Inc.$240
- Greenwich Biosciences, Inc.$232
- plus $761 from 12 others
Across 1 payment — averaging $1222.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$1K
What the payments were for
- Consulting fees$2407%
- Food & beverage$3,23793%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 31 | $1,144 |
| UCB, Inc. | 18 | $493 |
| SK Life Science, Inc. | 4 | $357 |
| Immedica Pharma US, Inc. | 3 | $254 |
| Sentynl Therapeutics, Inc. | 1 | $240 |
| Greenwich Biosciences, Inc. | 2 | $232 |
| Xeris Pharmaceuticals, Inc. | 3 | $205 |
| Neurelis, Inc. | 3 | $123 |
| AbbVie | 1 | $99 |
| Livanova USA, Inc. | 4 | $72 |
| Sumitomo Pharma America, Inc. | 2 | $69 |
| Cvrx, Inc. | 1 | $59 |
| Sarepta Therapeutics, Inc. | 1 | $50 |
| Pyros Pharmaceuticals, Inc. | 1 | $31 |
| Biogen | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Zogenix Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,481 in reported general payments places this provider in the 80th percentile of 41 neurology with special qualifications in child neurology providers in Missouri.
See all neurology with special qualifications in child neurology providers in Missouri →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluoxetine Hcl | 17 | $344 |
| Hydroxyzine Pamoate | 16 | $143 |
| Levocetirizine Dihydrochloride | 19 | $135 |
| Omeprazole | 19 | $108 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Columbia
- Deron SharpeColumbia$8K
- Paul CarneyColumbia$2K
- Nitin PatelColumbia$763
- Ahmed AbdelmoityKansas City$1.1M
- Nico DosenbachSaint Louis$132K
- Craig ZaidmanSaint Louis$110K
- Dusit AdstamongkonkulSpringfield$9K
- Brian AalbersKansas City$6K
- Liu ThioSaint Louis$6K
- Bhooma AravamuthanSaint Louis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.